These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 26666278)

  • 1. [Cost-effective medical therapy of hepatitis C employing novel compensation models - pay for cure].
    Foerster F; Wörns MA; Galle PR; Schattenberg JM
    Z Gastroenterol; 2015 Dec; 53(12):1414-21. PubMed ID: 26666278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C Cure Is Associated with Decreased Healthcare Costs in Cirrhotics in Retrospective Veterans Affairs Cohort.
    Maier MM; Zhou XH; Chapko M; Leipertz SL; Wang X; Beste LA
    Dig Dis Sci; 2018 Jun; 63(6):1454-1462. PubMed ID: 29453610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [System-immanent incentives in the remuneration for psychiatry and psychosomatics : Analysis exemplified by treatment of alcohol-related disorders].
    Horter H; Zapp W; Driessen M
    Nervenarzt; 2016 Jul; 87(7):760-9. PubMed ID: 27251739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of novel treatment of hepatitis C virus in Lebanese patients.
    Nasser SC; Mansour H; Abi Nader T; Metni M
    Int J Clin Pharm; 2018 Jun; 40(3):693-699. PubMed ID: 29611014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic evaluation of early monotherapy versus delayed monotherapy or combination therapy in patients with acute hepatitis C in Germany.
    Dintsios CM; Haverkamp A; Wiegand J; Gerlach T; Wedemeyer H; Pape G; Manns MP; Krauth C
    Eur J Gastroenterol Hepatol; 2010 Mar; 22(3):278-88. PubMed ID: 19550347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic burden associated with patients diagnosed with hepatitis C.
    McCombs JS; Yuan Y; Shin J; Saab S
    Clin Ther; 2011 Sep; 33(9):1268-80. PubMed ID: 21840056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What is the cost-effectiveness of hepatitis C treatment for injecting drug users on methadone maintenance in New Zealand?
    Sheerin IG; Green FT; Sellman JD
    Drug Alcohol Rev; 2004 Sep; 23(3):261-72. PubMed ID: 15370005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Broad Hepatitis C Treatment Scenarios Return Substantial Health Gains, But Capacity Is A Concern.
    Van Nuys K; Brookmeyer R; Chou JW; Dreyfus D; Dieterich D; Goldman DP
    Health Aff (Millwood); 2015 Oct; 34(10):1666-74. PubMed ID: 26438742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model.
    Scott N; McBryde ES; Thompson A; Doyle JS; Hellard ME
    Gut; 2017 Aug; 66(8):1507-1515. PubMed ID: 27196586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct medical costs associated with the extrahepatic manifestations of hepatitis C virus infection in France.
    Cacoub P; Vautier M; Desbois AC; Saadoun D; Younossi Z
    Aliment Pharmacol Ther; 2018 Jan; 47(1):123-128. PubMed ID: 29044584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver disease burden and required treatment expenditures for hepatitis C virus (HCV) infection in Thailand: Implications for HCV elimination in the new therapeutic era, a population-based study.
    Wasitthankasem R; Vichaiwattana P; Siripon N; Posuwan N; Auphimai C; Klinfueng S; Thanetkongtong N; Vuthitanachot V; Saiyatha S; Thongmai C; Sochoo S; Pongsuwan N; Poovorawan K; Tangkijvanich P; Poovorawan Y
    PLoS One; 2018; 13(4):e0196301. PubMed ID: 29689073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NIH Consensus Statement on Management of Hepatitis C: 2002.
    NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Health economics of chronic infectious diseases: the example of hepatitis C].
    Wasem J; Sroczynski G; Aidelsburger P; Buchberger B; Hessel F; Conrads-Frank A; Peters-Blöchinger A; Kurth BM; Wong JB; Rossol S; Siebert U
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Jan; 49(1):57-63. PubMed ID: 16341606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A clinician's guide to the cost and health benefits of hepatitis C cure assessed from the individual patient perspective.
    McEwan P; Selvapatt N; Brown A; Thursz M; Bennett H; Webster S; Kalsekar A; Yuan Y; Brenner M; Gordon J
    Eur J Gastroenterol Hepatol; 2017 Feb; 29(2):208-214. PubMed ID: 27832039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic model of a birth cohort screening program for hepatitis C virus.
    McGarry LJ; Pawar VS; Panchmatia HR; Rubin JL; Davis GL; Younossi ZM; Capretta JC; O'Grady MJ; Weinstein MC
    Hepatology; 2012 May; 55(5):1344-55. PubMed ID: 22135116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paying for quality not quantity: a wisconsin health maintenance organization proposes an incentive model for reimbursement of chiropractic services.
    Pursel KJ; Jacobson M; Stephenson K
    J Manipulative Physiol Ther; 2012 Jul; 35(6):472-6. PubMed ID: 22926019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimating the cost-effectiveness of needle-syringe programs in Australia.
    Kwon JA; Anderson J; Kerr CC; Thein HH; Zhang L; Iversen J; Dore GJ; Kaldor JM; Law MG; Maher L; Wilson DP
    AIDS; 2012 Nov; 26(17):2201-10. PubMed ID: 22914579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term disease and economic outcomes of prior authorization criteria for Hepatitis C treatment in Pennsylvania Medicaid.
    Kabiri M; Chhatwal J; Donohue JM; Roberts MS; James AE; Dunn MA; Gellad WF
    Healthc (Amst); 2017 Sep; 5(3):105-111. PubMed ID: 27932263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accuracy of budget impact estimations and impact on patient access: a hepatitis C case study.
    Geenen JW; Boersma C; Klungel OH; Hövels AM
    Eur J Health Econ; 2019 Aug; 20(6):857-867. PubMed ID: 30953216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Quality of care and health economics in occupationally acquired hepatitis C in German health care workers between 1993 and 2004].
    Reiser M; Haverkamp A; Dintsios M; Mölleken C; Krauth C; Pieper W; Schmiegel W
    Dtsch Med Wochenschr; 2007 Aug; 132(34-35):1743-7. PubMed ID: 17713882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.